Pipeline Overview
  • Focused on US solid tumor cancer market​
  • Rapid proof of concept and generation of clinical data in China IRB1 approved trials ​
  • U.S. clinical trials benefit from preliminary validation in IRB trials​
  • A comprehensive pipeline is under development with multiple IRB trials recruiting subjects